Skip to main content
. Author manuscript; available in PMC: 2024 Jan 26.
Published in final edited form as: Int J Gynecol Cancer. 2022 Jul 4;32(7):869–874. doi: 10.1136/ijgc-2021-003340

Table 4.

Recurrence-free survival for low risk endometrial cancer patients (grade 1 or 2 endometrioid histology, no lymphatic/vascular space invasion, less than 50% myometrial invasion) who did not receive any adjuvant therapy. CI, confidence interval; NE, not evaluable.

CTNNB1 mutation status N Events Median Recurrence-Free Survival, in years (CI) P-value
Wildtype 91 19 11.3 (5.3 – NE)
Mutant 27 6 8.1 (2.8 – NE)
0.65